An expert discusses the potential that several novel therapies hold in treating metastatic breast cancer, including PARP inhibitors, immunotherapy and antibody drug conjugates. Each therapy type has an FDA-approved option to potentially provide patients with better outcomes and quality of life.
In the field of lung cancer, a number of current studies evaluating the efficacy of adoptive cellular therapies may one day offer patients with non-small cell lung cancer a “high risk, high reward” treatment option, according to Dr. Ben Creelan of the Moffitt Cancer Center.
View the full CURE Educated Patient Multiple Myeloma Summit on demand.
As the population ages, the incidence of older adults being diagnosed with lung cancer is increasing, though data on how to specifically treat this population are lacking.
Targeted therapies that attack cancer in a more precise way than traditional chemotherapy are being used more often in the field of breast cancer, but the solution in utilizing them lies within the patient-oncologist relationship, according to an expert from the Massachusetts General Hospital Cancer Center.
An expert discusses ways that small cell lung cancer is diagnosed, how to treat it and how to pivot if the disease spreads or recurs. He also focuses on efforts in the clinical trial space to potentially treat patients more effectively.
Mindfulness practices have been associated with improved mental health outcomes in patients with cancer. Here, an expert shares tips on how patients can strengthen their “mindfulness muscle.”
With more than 4 million breast cancer survivors in the U.S., survivorship care and understanding what happens to patients after surviving is of the utmost importance. An expert explains some side effects survivors may experience and treatments to help.
View the full CURE Educated Patient Breast Cancer Summit on demand.
View the full CURE Educated Patient Lung Cancer Summit on demand.
A cancer diagnosis often comes with concerns of what’s next for patients. One concern is how they’re going to afford their treatments. Here, a panel of experts discuss what options are available.
There are two myths that patients with cancer believe when it comes to being health advocates. Here, a panel of experts look to dispel those myths to help patients become better advocates.
Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.
There are several health equity barriers in patients with cancer, one of which involves adequate access to clinical trials. Here, a panel of experts and a cancer survivor discuss ways to improve access.
The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.
Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.
The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.
Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.
For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.
Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.
The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.
Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.
A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.
The combination of Lenvima plus everolimus was found to be an acceptable treatment option for patients who have previously received immunotherapy for clear cell renal cell carcinoma, according to the findings of an exploratory analysis of a phase 2 trial presented virtually at the 2021 ASCO Genitourinary Cancers Symposium.
View the full CURE Educated Patient Women's Cancer Summit on demand.
View all three sessions of the CURE Educated Patient Lung Cancer Summit here!
More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.
Approximately half of the patients with breast cancer who failed anti-nausea or vomiting therapy for chemotherapy-induced nausea/vomiting during their first cycle of treatment failed to avoid the side effect at some point during the next three treatment cycles.
Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.
